Drilldown: Medicines

Fluorouracil (5-FU) (1) · Sodium bicarbonate (1)

Efudex (topical), Carac (topical), Fluoroplex (topical); generic IV (1) · Neut, many generic; OTC oral: Alka-Seltzer (with aspirin/citric acid), baking soda (1)

[[:Category:Antacids|Antacid]] (1) · [[:Category:Antimetabolites|Antimetabolite (pyrimidine analog)]] (1) · [[:Category:Antineoplastics|Antineoplastic]] (1) · [[:Category:Electrolyte_replacements|Electrolyte replacement]] (1)

None (1) · '"`UNIQ--vote-00000016-QINU`"' Bicarbonate is not benign: high-volume use produces hypernatremia, metabolic alkalosis, hypokalemia, and (in arrest) paradoxical intracellular acidosis'"`UNIQ--ref-00000017-QINU`"'. (1)

'"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"' (1) · '"`UNIQ--vote-000011BA-QINU`"', '"`UNIQ--vote-000011BB-QINU`"', '"`UNIQ--vote-000011BC-QINU`"', '"`UNIQ--vote-000011BD-QINU`"' (1)

IV: 1 mEq/kg bolus in arrest indication, then titrated to ABG and clinical status; PO: 325-2000 mg up to QID as antacid (1) · Topical: 0.5-5% cream/solution to lesions BID × 2-4 weeks; systemic IV: regimen-specific in cancer chemotherapy (1)

0.5% (Carac), 1% (Fluoroplex), 5% (Efudex) topical creams/solutions; 50 mg/mL IV (1) · 4.2%, 7.5%, 8.4% IV (1 mEq/mL at 8.4%); 325, 650 mg oral tablets; bulk powder (1)

No fixed maximum; titrated to pH and bicarbonate level; chronic high oral doses cause metabolic alkalosis and volume overload (1) · Topical: nightly; systemic: regimen-specific (1)

None · Oral · IV · Topical · IM · intranasal · rectal · Subcutaneous · topical ophthalmic · ophthalmic · intramuscular · intravenous · transdermal · vaginal · Subcutaneous (abdomen · Sublingual · thigh · inhaled · SC · intra-articular

Other values:

Search

Immediate (IV); within minutes (oral antacid) (1) · Topical: inflammation, erythema, crusting at 2 weeks; complete response weeks to months after course (1)

None · 24 hours · 4-6 hours · 12 hours · 6-8 hours · Daily dosing · 8-12 hours · 12-24 hours · Hours · Hours per application · 24 hours (HS dosing) · 24 hours (once-daily dosing) · 24 h · N/A · N/A (replacement) · Variable · ~7-8 hours · 3-5 hours · 4-6 hours (IR); 24 hours (ER) · 6-12 hours

Other values:

Search

Not applicable (electrolyte and buffer) (1) · ~10-20 minutes systemically (rapid hepatic and erythrocyte dihydropyrimidine dehydrogenase clearance)'"`UNIQ--ref-000011BE-QINU`"' (1)

100% (IV); rapidly neutralized by gastric acid (oral) (1) · Topical: minimal systemic absorption (oral systemic 5-FU not used due to poor and variable absorption)'"`UNIQ--ref-000011BF-QINU`"' (1)

Routine antacid and acidosis correction acceptable (1) · Topical: avoid; systemic: contraindicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

[[USLegal:Prescription only|Rx-only]] for IV formulations; OTC for oral (1) · [[USLegal:Prescription only|Rx-only]] in US (1)